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In Brief
Ruegsegger et al. show that interlinked pre-and postsynaptic deficits contribute to SCA1 pathogenesis, involving reduced Homer-3 expression and mTORC1 signaling in Purkinje cells. Deletion of mTORC1 led to reduced Homer-3 levels and accelerated disease while restoring Homer-3 alleviated pathology.
INTRODUCTION
Mechanisms determining selective vulnerability of neurons in neurodegeneration remain enigmatic. Identification and precise understanding of those mechanisms will provide immense insights into the pathophysiology of neurodegenerative diseases (NDs) as well as benefit the development of therapeutic targets. Spinocerebellar ataxia type 1 (SCA1) is a fatal, progressive autosomal ND whereby cerebellar Purkinje cells (PCs) selectively degenerate (Bü rk et al., 1996; Zoghbi and Orr, 2009 ). SCA1 is caused by an abnormal expansion of an unstable CAG trinucleotide repeat tract in exon 8 of ATXN1, causing an expanded polyglutamine tract in the Ataxin-1 protein (Banfi et al., 1994; Orr et al., 1993) . Despite the ubiquitous expression of the mutant protein in the CNS, selective degeneration of cerebellar PCs, complemented with losses in the brain stem and spinocerebellar tracts, are the predominant hallmarks of the pathology (Zoghbi and Orr, 1995) .
Knockin mice harboring an expansion of 154 CAG repeats in the endogenous mouse locus (Sca1 154Q/2Q ) ubiquitously express mutant Ataxin-1 and develop progressive neurodegeneration closely resembling the human SCA1 disease (Watase et al., 2002) . Studies using SCA1 mice models elucidated that PC loss in the cerebellum occurred late in disease, and early macroscopically visible symptoms could not be accounted for by PC degeneration alone (Clark et al., 1997; Zu et al., 2004) . The B05 mouse model, in which human Ataxin-1 harboring 82 polyglutamine repeats is overexpressed within PCs, allowed the identification of the physiological as well as the pathological role of Ataxin-1. Mainly, the interaction of Ataxin-1 with important transcription factors and RNA (Lam et al., 2006; Serra et al., 2004; Tsuda et al., 2005; Yue et al., 2001) suggested that alterations within these interactions dramatically alter the transcriptional landscape of PCs. Gene profiling experiments done on B05 mice demonstrated that mutant mice exhibit altered expression profiles for genes involved in glutamate signaling and calcium homeostasis (Lin et al., 2000; Serra et al., 2004) . Subsequently, it was found that the polyglutamine elongation in Ataxin-1 destabilizes RORa, an important transcriptional factor required for PC and cerebellar development (Harding et al., 1997) . The loss of RORa-mediated gene expression during development is an important determinant for PC vulnerability in SCA1 (Serra et al., 2006) . Further, synaptic inputs onto PCs arising from climbing fibers (CFs) are altered, leading to reduced CF-PC synaptic strength and concomitant alterations in PC excitability, which correlate with mutant Ataxin-1 expression. Alterations in parallel fiber (PF)-PC synapses were not observed at presymptomatic stages (Barnes et al., 2011; Duvick et al., 2010; Ebner et al., 2013) , suggesting the existence of selectively vulnerable components within the cerebellar circuit. However, the molecular pathways and mechanisms associated with CF impairments, as well as the consequences of these alterations in PCs and their impact on disease progression, remain unclear.
Here, we set out to determine the molecular alterations in mutant PCs and the relationship of these changes with respect to impaired synaptic inputs and dysfunctional PC excitation in SCA1. Using a mass spectrometry (MS)-based approach to mice delayed disease hallmarks and improved behavioral outcome. We identify mTORC1 signaling and Homer-3 as important components influencing the clinical manifestations and progression of disease in SCA1 mouse model.
RESULTS

Widespread Alterations in the Synaptic Proteome of Early Symptomatic
The first measurable pathology in Sca1 154Q/2Q arises by the fifth postnatal week (Watase et al., 2002) , right after the critical period for cerebellar maturation. Here, we focused on identifying the cellular processes which would be altered at this early age. We compared the total cerebellar proteome of wild-type (WT) and Sca1 154Q/2Q mice at post-natal day P35 by MS. A total of 675 proteins were detected and shared between both genotypes. Only proteins with a minimum PMSS (protein match score summation) of 30 and 3 or more unique peptides and detected in 2 separate experiments were analyzed. Of the 675 proteins detected, 85% remained unchanged, suggesting a high degree of reliability in our approach ( Figure 1A ). This semiquantitative analysis revealed an altered proteome; 68 proteins were upregulated and 32 were downregulated at least 2-fold. PANTHER (protein analysis through evolutionary relationships) revealed an enrichment for proteins belonging to diverse classes such as oxidoreductases, membrane-associated trafficking proteins, calcium-binding proteins, chaperones, etc. ( Figure S1A ). We validated some of these alterations by immunostaining; a representative example for increased expression of Synaptophysin and Excitatory Amino Acid Transporter 1 (EEAT1) in Sca1 154Q/2Q mice is shown in (Figures S1B and S1C ).
We next aimed to identify specific alterations within the PC proteome by laser dissecting groups of PCs from the most affected cerebellar lobules VIII-X from P35, WT, and Sca1 154Q/2Q mice. In parallel, from the same sections, groups of GCs from lobules VIII-X were collected and MS analysis was performed. Enrichment analysis for neuron-specific markers such as Calbindin, VGluT1, Parvalbumin, and Calretinin validated the purity of the extracted cellular proteomes ( Figure S1D ). Because GCs resist disease until end stage, we hypothesized that alterations within the PC proteome that were not observed within GCs might not only elucidate PC-specific alterations but also provide clues to early disease-associated changes. MS analysis revealed that 31% of Sca1 154Q/2Q PC proteome was significantly altered compared to WT ( Figure 1A ). An overrepresentation analysis on the proteins altered in PCs revealed significant enrichment for calcium-binding and membrane-trafficking proteins. The most significant molecular pathway altered in PCs was related to synaptic vesicle trafficking ( Figure 1B) . Interestingly, the large majority of detected calcium-binding proteins involved in regulating calcium dynamics were downregulated in Sca1 154Q/2Q PCs ( Figure 1C ). These included Calmodulin, Hippocalcin-like protein 1, neuron-specific calcium-binding proteins, Calreticulin, and serine/threonine-protein phosphatase 2A/B catalytic subunit alpha isoform ( Figure 1D ). Further, proteins localized to the synapse and involved in synaptic vesicle priming, vesicle exocytosis, and synaptic transmission were significantly reduced in Sca1 154Q/2Q ( Figure 1D ). A comparison between alterations within the total cerebellar proteome and PC-specific proteome revealed four conserved alterations: neuromodulin, glutamate receptor delta-2 subunit (GluD2), Homer-3, and vesicle-associated membrane protein 2 (VAMP-2) ( Figure 1E ). Moreover, the alterations identified were disease and PC specific as the same proteins remained unaltered in GCs ( Figure S1E ). For complete list of altered proteins, see Table S1 .
Early and Persistent Reduction in Homer-3 Expression in Sca1 154Q/2Q PCs We focused our attention on Homer-3 because it is enriched in PC dendrites and spines (Shiraishi et al., 2004) and is involved Figure S1 .
in the physical and functional coupling of metabotropic glutamate receptor 1 (mGluR1) and inositol-1,4,5-triphosphate receptor (IP 3 R) (Brakeman et al., 1997; Tu et al., 1998) , thereby regulating neuronal activity. Immunostaining for Homer-3 at various ages in disease revealed that PC spines presented consistently reduced Homer-3 levels ( Figure 2A ). This reduction was also observed by immunoblotting the total cerebellar lysates for Homer-3 at various ages in disease ( Figure 2B ). In order to exclude the possibility that alteration in Homer-3 levels was due to degeneration of dendritic spines rather than the reduced expression of Homer-3, cerebellar synaptosomes were isolated from WT and Sca1 154Q/2Q mice ( Figure 2C 
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Homer-3 Immunoblotting for Homer-3 revealed an early reduction in Homer-3 levels as from P40 in Sca1 154Q/2Q mice, whereas dendritic spine marker PSD-93 remained unchanged, excluding that early reduction in Homer-3 expression was due to spine loss ( Figure 2D ). We measured mRNA levels of Homer-3 and found no significant decline in Homer-3 transcripts from P20 until P120. A 2-fold reduction in Homer-3 mRNA was observed as from P150, Sca1 154Q/2Q ( Figure 2E ), suggesting that the initial reduction in Homer-3 protein levels was not mRNA related. We also measured the expression of the short-form Homer-1a as it blocks interaction of Homer-3 to mGluR1 and found no alterations in its expression ( Figures S2A and S2B ).
Homer-3 Expression Is Modulated by Enhancing Glutamatergic Transmission
Since mutant Ataxin-1 impairs the expression of genes associated with glutamate signaling (Lin et al., 2000; Serra et al., 2004) , we hypothesized that reduced Homer-3 levels were a reflection of dysfunctional glutamate-mediated signaling. Mimicking impairments in glutamatergic signaling by inhibiting glutamate receptors via AMPA-Kainate receptor antagonist CNQX led to a significant reduction in Homer-3 immunolabeling in the molecular layer (ML) of both WT and Sca1 154Q/2Q mice (Figure 3A) . As CFs are the major source of excitatory inputs to PCs, CF synapses onto PCs were destroyed by 3-acetylpyridine (3-AP) administration (Balaban, 1985) . Similar to CNQX treatment, 3-AP treatment led to a pronounced reduction in Homer-3 levels in WT condition, and in Sca1 154Q/2Q cerebellum, Homer-3 levels were further reduced ( Figure 3B ). These results indicated that expression of Homer-3 was modulated by glutamatergic signaling and that reduced Homer-3 levels reflected disease-associated alterations in this pathway. As mGluR1 activation stimulates the de novo protein synthesis in neurons leading to mGluR-dependent plasticity, we examined whether enhancing mGluR1 activation would restore Homer-3 levels. Application of a single dose of harmaline (Harma), a tremorgenic drug, selectively increasing the release of glutamate at the CF-PC synapse (Beitz and Saxon, 2004) , augmented Homer-3 labeling within WT PC spines, but not in Sca1 154Q/2Q PCs ( Figure 3C ). Next, we examined whether the direct activation of mGluR1 via cerebellar injection of type I mGluR agonist DHPG would influence Homer-3 levels. Pharmacological activation of mGluR1 significantly increased Homer-3 labeling intensities within WT dendritic spines. Again, the same treatment did not affect Homer-3 levels in Sca1 154Q/2Q PCs (Figure 3D ). Although our proteome analysis did not reveal early changes in mGluR1 expression levels, we examined whether alterations in its expression per se influenced Homer-3 expression. Immunolabeling for mGluR1 revealed comparable expression for mGluR1 between WT and Sca1 154Q/2Q mice at P40 (age when MS was performed) and P100 (symptomatic age) ( Figure S2C ).
Early Alterations in CF Connectivity and CF-PC Synaptic Transmission in Sca1
154Q/2Q Mice Studies examining PC circuit in B05 mouse model revealed reduced PC responsiveness to CF activation and reduced CF translocation along the PC dendritic tree at early ages (Barnes et al., 2011; Ebner et al., 2013) . We examined whether similar alterations would impact Sca1 154Q/2Q PC responsiveness to Harma-induced CF activation. We used VGluT2 as a marker for CF terminals and found significant and persistent reduction in the volume of VGluT2-positive puncta in Sca1 154Q/2Q ML. In total, 48% of mutant VGluT2-positive puncta displayed volumes smaller than 3 mm 3 compared to 27% in WT at P30 ( Figure 4A ).
Additionally, an increase in the number of VGluT2-positive puncta onto PC dendrites in Sca1 154Q/2Q compared to WT animals was observed ( Figure 4B ), indicating that a substantial proportion of CF terminals in Sca1 154Q/2Q were smaller in volume but numerous. Measurement of the CF territory onto PC dendrites revealed significant reduction in CF innervation territories in Sca1 154Q/2Q ( Figure 4C ). Next, we examined the functionality of the CF-PC synapse by measuring the CF-mediated excitatory postsynaptic currents (CF-EPSCs) in WT and Sca1 154Q/2Q mice at two distinct ages: P50 and P100. The CF-EPSCs were evoked by applying a current of 5-100 mA, CFs were detected in a range of 5-30 mA, the intensity of the stimulation was progressively increased, and the amplitude of the postsynaptic response was measured. A significant difference in the kinetics of CF-EPSCs was observed: the 10%-90% rise time and the decay time constant of the CF-EPSCs were significantly reduced, whereas the 10%-90% rise slope was significantly increased in Sca1 154Q/2Q mice ( Figure 4D ). These measurements are indicative of the electrotonic length from the soma to the site of the synapse and suggest that CF-EPSCs in mutant PCs arise from synapses located electrotonically closer to the soma. Amplitudes of CF-EPSCs and paired-pulse depression (PPD) remained unaltered between WT and Sca1 154Q/2Q mice ( Figure 4D ).
We also analyzed passive properties of PCs calculated as previously described (Llano et al., 1991) . The lumped dendritic capacitance (C2) was significantly smaller at both P50 and P100 in the Sca1 154Q/2Q PCs, while no difference was observed in the lumped soma and proximal dendrite capacitance (C1) (Figure 4D) , suggesting that the average total membrane area of the dendritic tree of the mutant PCs is smaller than that of WT PCs already at an early age in disease. No significant changes were observed in the lumped resistance (data not shown). Subsequently, ultrastructural analysis and measurements of synaptic vesicle pool occupancy within presynapses in the dendritic region proximal to PC somata where CF synapses are predominant revealed profound alterations in Sca1 154Q/2Q mice. In total, 85% of presynapses in Sca1 154Q/2Q presented a synaptic vesicle pool occupancy lower than 50%, whereas in the WT only 32% of the presynapses had less than 50% occupancy (Figure 4E) . To examine whether the reduced number of synaptic vesicles could impact PC responsiveness, we measured the miniature EPSCs (mEPSCs) in PCs and found no alterations in the amplitude of the mEPSCs at P50 and P100 in mutant condition. In contrast, the frequency of mEPSC showed a trend to be reduced by P100 in mutant PCs compared to WT PCs ( Figure 4F ), suggesting that spontaneous release of synaptic vesicles was reduced.
In order to examine whether alterations in CF inputs might influence PC activation, we measured the activation state of PCs via the nuclear translocation of immediate early gene c-Fos, induced in response to neuronal activity. For CF-induced PC activation, a protocol based on the activation of CFs via Harma was used ( Figure S3A ). After Harma treatment, inferior olive (IO) neurons exhibited nuclear c-Fos to a similar extent in both WT and Sca1 154Q/2Q mice ( Figure S3B ), indicating that the activation state of IO neurons per se was not altered in disease. In total, 10% of PCs in WT mice presented strong nuclear c-Fos staining after 100 min of Harma treatment, which increased to 20% at 150 min and decayed by 300 min. However, the nuclear c-Fos responses were largely reduced within Sca1 154Q/2Q PCs ( Figure S3C ).
Reduced mTORC1 Signaling in Sca1
154Q/2Q PCs Neuronal activity is associated with the downstream activation of critical signaling pathways such as mTORC1, which in turn regulates protein translation, a prerequisite for synaptic plasticity (Gong et al., 2006 Figure 5A ). S6 expression remained unchanged between WT and Sca1 154Q/2Q mice, ruling out that lower S6 levels led to reduced phosphorylation of S6 ( Figure 5B ). As further evidence for reduced mTORC1 signaling, the phosphorylated levels of mTORC1-dependent translation regulator 4E-BP1 were reduced by 35% in Sca1 154Q/2Q cerebellum ( Figure S4A ). To confirm that glutamatergic signaling regulates mTORC1 activation in PCs, WT mice were treated with GluR antagonist CNQX or with 3-AP. Both treatments led to a significant reduction in pS6 immunolabeling in PCs ( Figures 5C and 5D ). Conversely, increasing mGluR1 receptor activation via application of DHPG strongly increased pS6 levels within WT PCs. However, the same treatment did not increase pS6 levels in Sca1 154Q/2Q PCs ( Figure 5E ), suggesting that alterations in synaptic signaling in mutant PCs might impact the activation of mTORC1 pathway. To validate that impairment in mTORC1 signaling was mutant PC-specific and arose due to dysfunctional synaptic transmission, we measured pS6 levels in the Sca1 154Q/2Q brain and found no alterations in pS6 expression within the various brain regions examined ( Figures S4B-S4D ). As Sca1 154Q/2Q mice ubiquitously express mutant Ataxin-1, this suggests that mutant Ataxin-1 does not directly interfere with mTORC1 signaling. Since Ataxin-1 interacts with transcriptional regulators and influences transcription (Crespo-Barreto et al., 2010) , mRNA levels of important components of the mTORC1 pathway (Mtor, Eif4b, and RpS6) were measured, revealing no alterations ( Figure S4E ).
Homer-3 Expression Is Controlled by mTORC1 Pathway
As mTORC1 signaling pathway is implicated in activity-dependent protein synthesis, thereby regulating forms of synaptic plasticity, we examined how impairment in mTORC1 pathway might specifically affect the expression of proteins involved in plasticity-dependent mechanisms. To identify mTORC1 signalingdependent proteins, P20, WT mice were treated with mTORC1 inhibitor Rapamycin (Rapa). Immunolabeling and immunoblotting for pS6 from total cerebellar lysates, as well as from sequential cerebellar sections, confirmed the success of the treatment, as pS6 levels were negligible after Rapa treatment ( Figure 6A ). PCs and GCs were isolated via laser-capture microdissection (LDM) from age-matched WT, WT-Rapa, and Sca1 154Q/2Q littermates, and lysates were subjected to MS analysis. In order to obtain candidates having an mTORC1-dependent expression, we first compared WT-Rapa PC to WT PC proteomes. The candidates so obtained were compared to the ones altered in PCs from Sca1 154Q/2Q versus WT. This provided candidates whose expression was mTORC1 dependent and altered in disease ( Figure 6A ). Of 90 proteins detected and altered in Sca1 154Q/2Q PCs (cut off PMSS at 30, 3 or more unique peptides), 41% of the proteins revealed an mTORC1-dependent expression pattern, whereas 59% of the altered proteins were mTORC1 independent. On the contrary, in GCs, 23% of the proteome was altered, of which only 16% exhibited mTORC1 dependence ( Figure 6B ). These results suggest that PCs might be substantially more dependent on mTORC1-regulated expression of proteins and that alterations in mTORC1 signaling might strongly affect PC-specific proteome composition. Interestingly, expression of Homer-3 as well as calcium-binding proteins within PCs was mTORC1 dependent (Figure 6C) . For a complete list of mTORC1-dependent PC-and GCspecific proteins, see Table S2 . WT and Sca1 154Q/2Q mice were treated with Rapa, followed by immunolabeling for Homer-3. Homer-3 levels were strongly reduced within dendrites in both WT and Sca1 154Q/2Q cerebellum, confirming that Homer-3 expression was regulated by mTORC1. Immunoblotting revealed that Rapa treatment reduced pS6 levels without affecting S6K expression. Similarly, Homer-3 expression was reduced after Rapa treatment without reduction in PSD-93 ( Figure 6D ). To gain insights into Homer-3 production and mTORC1-mediated regulation of Homer-3, neuroblastoma cells were transiently transfected with Homer-3 and were treated with Rapa for 12 hr or 36 hr. A progressive decline in Homer-3 levels was observed after Rapa, which was not observed for GAPDH. Dual treatments with protein translation blocker cycloheximide (CHX) and lysosomal blocker ammonium chloride (NH 4 Cl) or proteasomal blocker lactacystin revealed that Homer-3 was preferentially degraded via the proteasome ( Figure S5A ). We also assessed whether reduction in mTORC1 pathway was a compensatory mechanism for autophagy induction. Analysis of Sca1 154Q/2Q PCs until P150 revealed absence of autophagy ( Figures S5B-S5F ).
PC-Specific Ablation of mTORC1 Anticipates Disease Pathology
We examined whether alterations in mTORC1 and Homer-3 expression would causally affect disease pathology. As Rapa treatment lacks specificity and targets the entire cerebellum, we took a conditional approach whereby mTORC1 pathway was genetically ablated within PCs via the disruption of the adaptor protein Raptor (regulatory-associated protein of intensity in lobule IX, n = 12 sections each from 3 mice. Data presented as box and whiskers (min, max), one-way ANOVA with Tukey's Multiple Comparison Test: *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar, (A-D) 10 mm. See also Figure S2 . (legend on next page) mTOR). As depicted in (Figure 7A ), a floxed Rptor mouse was crossed with a Cre under L7/Pcp2 promoter driver line, leading to the Rptor gene being knocked out within PCs (RAPuKO), thereby inhibiting mTORC1 pathway specifically within PCs. Immunolabeling for pS6 confirmed the successful inhibition of the mTORC1 pathway within 66% of PCs ( Figure 7A ). Subsequently, immunolabeling for Homer-3 in RAPuKO cerebellum revealed that PCs depleted of Raptor identified by their small soma size and lack of pS6 immunoreactivity, presented negligible levels of Homer-3 ( Figure 7B ). Homer-3 levels were reduced in PC soma, spines, and dendrites in an age-dependent manner, but no alterations in Homer-3 mRNA levels were detected (Figure 7C) . Conversely, we enhanced mTORC1 activation within PCs using a floxed tuberous sclerosis protein 1 (Tsc1) mouse strain crossed with Cre under L7/Pcp2 promoter driver line to generate TSCPuKO mice. Immunolabeling revealed hypertrophic Tsc1 knockout PCs showing high pS6 and Homer-3 levels, confirming that Homer-3 expression is mTORC1 dependent (Figures S6A and S6B) . Note the presence of abnormal dendrite arbors on hypertrophic PCs, immature CF inputs, and ataxia in TSCPuKO mice associated with high expression of mTORC1 early in development ( Figures S6C-S6E ).
To examine whether PC-specific mTORC1 dysfunction impacts disease progression, we generated Sca1 154Q/2Q -RAPuKO mice. As the earliest pathological hallmark of SCA1 is impairments in motor coordination and balance, we measured those behavioral paradigms. Minor and slowly progressing age-associated deficits on the rotarod were observed in RAPuKO mice compared to Rptor fl/fl mice (WT-ctr Figure 7D ). We examined CF terminal innervation in RAPuKO PCs by labeling them with AAV expressing GFP (AAV8.2:GFP). This strategy was used to specifically examine CF innervations onto RAPuKO PCs, as these mice are chimeras harboring a mixture of both WT and RAPuKO PCs. Significant reduction in CF innervation territory was observed in RAPuKO PCs, which was further reduced specifically in Sca1 154Q/2Q -RAPuKO PCs ( Figure 7E ), suggesting that mTORC1 signaling and/or Homer-3 protein expression might synergistically determine CF maturation and PC synaptic functioning. Figure 8B ). pS6 levels were increased in Sca1 154Q/2Q AAV8.2:Homer-3 PCs, suggesting the restoration of mTORC1 signaling after Homer-3 overexpression in PCs ( Figure 8C ). We next assessed CF innervation and found that CFs in AAV8.2:Homer-3-injected Sca1 154Q/2Q cerebellum presented innervation territories close to those observed in WT mice ( Figure 8D ). Ultrastructural analysis of synaptic vesicle pool occupancy within presynapses in the dendritic region proximal to PC bodies of Sca1
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AAV8.2:Homer-3 revealed a near-normal synaptic vesicle pool occupancy ( Figure 8E ). We further examined whether these CF-specific improvements would ameliorate PC activation. Virally transduced Sca1 154Q/2Q PCs displayed a higher number of nuclear c-Fos-positive PCs as compared to untransduced Sca1 154Q/2Q after Harma treatment ( Figure 8F ). As CaMKII-a is autophosphorylated upon increased intracellular calcium levels in response to neuronal activity (Miller and Kennedy, 1986 ), we measured p-CaMKII-a as an indicator of improved PC functioning. From P20, strong reduction in p-CaMKII-a labeling intensity was observed in Sca1 154Q/2Q mice, indicating that mutant
PCs have reduced neuronal activation responses. Total CaMKII-a levels remained largely unaltered at early disease 
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Homer-3 stage, and a minor decline in levels was observed at P150 (Figures S7D and S7E) . Overexpression of Homer-3 in mutant PCs restored p-CaMKII-a expression levels to near normal, like those observed in WT until late disease stage ( Figure S7F ). As further evidence for improved calcium-associated parameters, expression intensities for Calbindin and Calreticulin in Homer-3-overexpressing Sca1 154Q/2Q PCs were significantly higher than in mutant PCs ( Figure 8G ). Longitudinal quantification of spine density revealed sustained and normal spine numbers in Sca1 154Q/2Q AAV8.2:Homer-3 PCs compared to Sca1
PCs. Moreover, PC numbers remained unchanged in Homer-3-expressing mutant PCs, whereas reduced PC numbers, suggestive of PC loss, were observed in Sca1 154Q/2Q ( Figure 8H ).
AAV8.2:Homer-3 was also used to examine whether lowered mTORC1 activation could impact Homer-3 turnover in mutant PCs. RAPuKO mice were transduced with AAV8.2:Homer-3, and Homer-3 intensity measurements from RAPuKO PCs and adjacent WT PCs ruled out accelerated turnover of Homer-3 in case of mTORC1 ablation ( Figure S7G ).
DISCUSSION
Alterations in intrinsic neuronal excitability, intracellular calcium dynamics, and associated neuronal circuits have been observed in NDs (Bezprozvanny, 2010; Roselli and Caroni, 2015) . In this context, it is essential not only to identify the molecular basis for these alterations at cellular and neuronal circuit level but also to understand the precise interplay between these alterations during disease progression. Previous gene profiling studies using B05 mouse model had identified altered glutamatergic signaling in SCA1 PCs (Lin et al., 2000; Serra et al., 2004) . However, it remained unclear how reduced transcripts of Homer-3, G-substrate, EEAT4, IP3R, and CARP contributed to SCA1 pathophysiology. Here, we investigated the early alterations within the PC proteome, which provided a snapshot of impairments that might be causally linked with SCA1 pathogenesis. Proteome analysis of P35, Sca1 154Q/2Q PCs revealed substantial alterations within proteins involved in intracellular calcium binding and synaptic transmission, such as Homer-3. Homer-3 is an adaptor protein present in the postsynaptic density that binds to mGluRs, IP3Rs, and NMDA receptor adaptor Shank (Brakeman et al., 1997; Hayashi et al., 2009; Tu et al., 1998) . The phosphorylation of Homer-3 via activated CaMKII-a leads to its dissociation from mGluRs (Mizutani et al., 2008) . Disruption or imbalance in Homer scaffolds is linked to impaired mGluR5 signaling in fragile X syndrome (FXS) (Ronesi et al., 2012) . Similarly, mutations causing reduced expression of NMDA receptor scaffold SynGAP are implicated in autism and intellectual disability (Hamdan et al., 2011) . Mutations in gene encoding the scaffolding proteins SHANK are associated with autism spectrum disorders (Berkel et al., 2010; Jiang and Ehlers, 2013) .
Reduced Homer-3 levels in Sca1 154Q/2Q found as early as P35
suggest that not only mGluR1 signaling but also synaptic plasticity within the spine is affected in SCA1. This was mainly reflected in the proteomic profile of PCs, which indicated large alterations within the synaptic proteome. Studies in the KO mouse model of human FXS have revealed impairments in mGluR signaling-dependent rapid protein synthesis (Todd et al., 2003; Weiler et al., 2004) . These impairments mainly arise from reduced association of mGluRs to long-form Homer, causing the selective inhibition of PI3K-Akt-dependent activation of mTORC1 signaling and downstream protein synthesis (Ronesi and Huber, 2008) . In this context, our finding that mGluR1 levels are not altered at early symptomatic ages in Sca1 154Q/2Q PCs, while Homer-3 levels were significantly reduced, hints toward an impaired association between the two, leading to the observed reduction in mTORC1 activation and dependent protein synthesis. We questioned which mechanisms could regulate Homer-3 in PCs and how they would be impaired in Sca1 154Q/2Q . Enhancing PC activation via Harma treatment, causing increased release of glutamate selectively from CF inputs, led to higher Homer-3 levels in WT PCs. However, Homer-3 levels in mutant PCs were not affected, which is related to the observation that CF synapses in mutant condition display significantly reduced synaptic vesicle occupancy. This could impact the amount of available synaptic vesicles for glutamate release upon Harma treatment. Furthermore, the frequency of mEPSCs was reduced in P100 mutant PCs compared to WT PCs, indicating that spontaneous release of synaptic vesicles was lower. The fact that this reduction remained a trend could be explained as we cannot distinguish between CF-and PF-mediated release of synaptic vesicles and because 15%-20% of the presynapses show normal vesicle pool occupancy in Sca1 154Q/2Q . Moreover, the direct activation of mGluR1 via DHPG led to robust increase in Homer-3 expression in WT PCs but did not change Homer-3 levels in mutant PCs. The nonresponsiveness of mutant PCs to DHPG treatment can be accounted for by the fact that diminished Homer-3 levels might lead to suboptimal coupling of mGluR1, thereby impairing downstream glutamate signaling, mTORC1 activation, and protein translation.
Examining downstream pathways associated with mGluR signaling revealed that Homer-3 expression was regulated by mTORC1 signaling, which was reduced by 40%-50% at P35 in Sca1 154Q/2Q PCs. At this early age, we were unable to detect other disease-associated factors that could negatively impact mTORC1 signaling such as oxidative or ER stress. Since reduction in Homer-3 was at translational level and mTORC1 is activated upon neuronal activity, thereby regulating protein translation (Gong et al., 2006; Lü scher and Huber, 2010; Ronesi and Huber, 2008) , a link between the two components might exist. The deletion of mTORC1 signaling specifically within PCs led to a decline in Homer-3 expression. Conversely, increasing mTORC1 signaling in PCs enhanced Homer-3 levels, confirming that mTORC1 activation regulates downstream expression of Homer-3. Taken together, this suggests that a dual mechanism involving altered presynaptic CF-PC transmission, along with postsynaptic alterations in Homer-3 expression and glutamatergic signaling, could converge onto mTORC1, impairing its signaling and further reducing Homer-3 expression. The importance of normal mTORC1 activation is demonstrated by the observation that deletion of mTORC1 signaling within Sca1 154Q/2Q PCs exacerbates disease pathology.
Reduced Akt/mTORC1 signaling pathway leading to altered translational control in neurons was found in a mouse model and in human embryonic stem cell model of Rett syndrome (Li et al., 2013; Ricciardi et al., 2011) . In NDs, altered mTORC1 signaling was observed in Huntington's disease (HD) (Lee et al., 2015) and amyotrophic lateral sclerosis (ALS) (Saxena et al., 2013) , while dysregulation of mTORC1 pathway was implicated in Alzheimer's disease (AD) (Ma et al., 2010; Yates et al., 2013) . Restoring mTORC1 signaling, thereby re-expressing mTORC1-dependent proteins, was shown to be neuroprotective in Parkinson's disease (PD) (Malagelada et al., 2006) . Strong developmental activation of mTORC1 signaling in TSCPuKO mice causes an immature cerebellum with deficits in CF innervation, as well as alterations in PC spine and dendrite morphology, making them unsuitable for experiments evaluating the rescue of SCA1 pathology. In this context, the heterozygous Tsc1 mice could be an alternative option; however, they exhibit similar autism-associated behavioral deficits and significantly higher spine density , which might interfere with genuine SCA1-related rescue readout. Therefore, we enhanced Homer-3 expression in mutant PCs in an attempt to improve glutamatergic signaling and downstream mTORC1 expression. Reinstating Homer-3 expression ameliorated CF deficits, enhanced mTORC1 signaling in PCs, and reduced spine loss, thereby providing evidence for the involvement of reduced Homer-3 and mTORC1 in SCA1. The expression and nuclear translocation of mutant Ataxin-1 in PCs were shown to be associated with abnormal CF inputs onto PCs and reduced PC responsiveness to CF stimulation in B05 model (Barnes et al., 2011; Ebner et al., 2013) . We provide evidence that similar deficits involving altered CF innervation and CF-PC synaptic transmission also exist in Sca1 154Q/2Q mice.
Moreover, genetic inhibition of mTORC1 signaling pathway influences the CF innervation pattern, and RAPuKO mice were shown to exhibit deficits in CF-EPSC kinetics (Angliker et al., 2015) . Homer-3 levels are reduced in RAPuKO PCs, suggesting that altered Homer-3 levels and/or mTORC1 signaling can lead to CF-associated deficits. It is intriguing that Homer-3 overexpression ameliorates CF deficits in disease. Studies have revealed a requirement for mGluR1-mediated signaling in CF synapses elimination (Hashimoto et al., 2001 ), a process required for correct CF innervation. Although the molecular mechanism involved in the amelioration of CF translocation onto PCs via Homer-3 expression remains unclear, our data suggest that rescuing Homer-3 levels in PCs helps in the efficient association of mGluR1 with IP3R, enabling downstream mGluR1-dependent signaling crucial for correct CF maturation. Of note is the finding that altered CF inputs, reduced Homer-3 levels, impaired mGluR1, and mTORC1 signaling are not isolated singular deficits but rather a complex continuous process that ultimately leads to feedback loops which impinge onto mGluR1 signaling ( Figure S8 ). However, it is unclear how mutant Ataxin-1 might influence these alterations in PCs. Mutant Ataxin-1 expression at early ages impairs RORa-mediated gene expression important for PC maturation and cerebellar development (Serra et al., 2006) . Similar future studies examining sg/sg model, having functional loss of RORa (Dussault et al., 1998) , will help in deciphering the role of decreased RORa-mediated gene expression in SCA1 pathology. Taken together, our data provide evidence for reduced Homer-3 expression being a critical determinant of disease and that its levels are regulated via mTORC1 signaling. Reinstating Homer-3 levels delays and attenuates symptoms of SCA1, thereby providing a novel avenue for therapeutic strategy.
EXPERIMENTAL PROCEDURES
Transgenic Mice
Animal care, housing (IVC cages), ethical usage, and procedures were in accordance with the Swiss Veterinary Law guidelines. The knockin SCA1 mice (B6.129S-Atxn1 tm1Hzo /J) (Watase et al., 2002) , termed Sca1
154Q/2Q
, were obtained from Jackson Laboratory.
Mice, homozygous for an allele containing loxP sites flanking exon 6 of the Rptor gene (Bentzinger et al., 2008) or flanking exon 17-18 of the Tsc1 gene (Kwiatkowski et al., 2002) , were crossed with L7/Pcp2-Cre transgenic mice (Saito et al., 2005) ;Tg were crossed into L7/Pcp2-Cre to give TSCPuKO mice that were L7/Pcp2-Cre homozygous with two floxed Tsc1 alleles. TSCPuKO mice were crossed with Sca1 154Q/2Q mice to obtain Sca1 154Q/2Q -TSCPuKO mice. As control for SCA1, TSCPuKO mice were used, and for KO of Tsc1, mice lacking Cre were used (WT-ctr and Sca1
-ctr).
Pharmacological Treatments
Drug administration was as follows: CNQX (Tocris Bioscience), given at 20 mM in drinking water. Rapamycin (LC Laboratories) was prepared as published (Meikle et al., 2008) , injected intraperitoneally (i.p.) at 6 mg/kg; (RS)-3,5-DHPG (Tocris Bioscience) was injected in the cerebellar vermis (2 ml of 250 mM in saline); Harma (Sigma) was injected i.p. at 20 mg/kg in saline; 3-AP (Sigma) was injected i.p. at 75 mg/kg in saline.
Laser-Capture Microdissection Anesthetized mice were sacrificed; cerebella were isolated, placed on a glass slide, frozen on dry ice, embedded in O.C.T. compound (Tissue Tek), and cryostat cut into 15 mm sections. Sections were transferred onto membrane slides (Membrane Slide 1.0 PET, ZEISS) and stored at À80 C. Prior to LDM, slides were thawed, stained with Toluidine blue (0.1% Toluidine blue in PBS), washed in 70% followed by 100% ethanol, and dried at RT.
PCs and GCs were collected by LDM using the PALM MicroBeam system (ZEISS). For PCs, 3,000,000 and for GCs, 2,000,000 mm 2 area were collected and transferred into capture tube caps (AdhesiveCap 500 opaque, ZEISS). Cells were lysed and proteins extracted in 10 ml RIPA buffer. Tubes were vortexed; centrifuged at 16,000 3 g, 4 C for 10 min; and stored at À80 C until MS.
Mass Spectrometry Analysis
Samples were loaded on 12% SDS-gel and run for 1 cm. Gel was stained with InstantBlue (Expedeon) for 2 hr. Lanes were cut into ten bands, and each band was cut into 4 pieces, destained with 30% ethanol for 20 min, and washed with 100% ethanol for 30 min followed by ddH 2 O for 30 min (cycle repeated thrice). The MS (shotgun LCMS/MS) was done at the MS and Proteomics Core Facility of the Department of Clinical Research, University of Bern. Each sample was measured thrice with a spectrum sampling approach, and the MaxQuant software was used to estimate the protein abundance (Heller et al., 2007) . For analysis, proteins with PMSS of at least 30 and detected with 3 or more unique peptides were taken into account. Panther Classification System Software was used for overrepresentation test and to map candidates into protein classes and pathways. Proteins showing 2-fold changes were analyzed. MS was performed in duplicate for full cerebellar lysate and in triplicate for PC and GC lysates.
Immunohistochemistry and Antibodies
Anesthetized mice were intracardiacally perfused with 0.1 M PBS (pH 7.4), followed by 4% paraformaldehyde (PFA) solution. Isolated cerebella were postfixed 24 hr at 4 C in 4% PFA solution and cryoprotected in 30% sucrose solution for 48 hr at 4 C. Cryostat-cut 50 mm free-floating sagittal sections were collected in 0.8% sodium-azide (AxonLab, in PBS). Sections were washed in PBS and blocked in 3% BSA Fraction V (Roche) for 2 hr at RT. For Homer-3 immunostaining, an antigen retrieval step was done prior to blocking by incubating the sections for 15 min at 80 C in sodium citrate buffer
